A Phase 2 interventional study of Brentuximab Vedotin and Cyclophosphamide in Lymphoma, sponsored by Takeda. Active, not recruiting at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing Brentuximab Vedotin in Lymphoma — 1 open to participants now, 3 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma.
Among the 32 studies testing Brentuximab Vedotin in Lymphoma, this one is the 14th largest by enrollment, is the only one that started in 2023, is one of 12 in phase 2, and was the 31st registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 32 studies testing Brentuximab Vedotin in Lymphoma is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in India
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 17 · Phase 3 3 · Phase 4 3
First in 2006; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 51 across the 32 interventional studies. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 32 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Lymphoma by Takeda: 1 open now, 2 under way, none of them phase 3. Of 24 finished, 17 (71%) have results posted.
Among the 26 studies in Lymphoma by Takeda, this one is the 10th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 2, and was the 25th registered.
Takeda’s Lymphoma studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing Brentuximab Vedotin in Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will use a combination of Brentuximab vedotin with CHP to treat adult Chinese participants with CD30+ PTCL.
The main aims of the study are to evaluate:
Brentuximab vedotin will be given through vein on Day 1 of each 21-day cycle. Cyclophosphamide and doxorubicin will be given through vein. Prednisone will be given orally daily on Days 1 through 5.
The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat CD30+ PTCL in Chinese participants. This study will look at the efficacy, safety, and pharmacokinetics (PK) of A+CHP as frontline treatment for newly diagnosed CD30+ PTCL.
The study will enroll approximately 52 participants. Participants will be enrolled in a single group to receive:
This multi-center trial will be conducted in China. The overall time to participate in this study is approximately 36 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have newly diagnosed CD30+ PTCL, per the Revised European American Lymphoma 2016 World Health Organization (WHO) classification, by local assessment. Tumor specimen must be submitted before enrollment for subsequent central pathology review to confirm histology (and anaplastic lymphoma kinase (ALK) status, if applicable), and CD30 expression. Eligible histologies include:
Clinical laboratory values as specified below at screening/baseline within 7 days before the first dose of study drug:
Exclusion Criteria:
Known virus (HBV) surface antigen (HBsAg) seropositivity or active virus infection.
Note: Participants who have positive HBV core antibody and are HBsAg negative can be enrolled, but must have an undetectable HBV viral load.
Any of the following cardiovascular conditions or values within 6 months before the first dose of study drug:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\^2 and doxorubicin 50 mg/m\^2 IV, on Day 1 of each 21-day cycle, and prednisone 100 milligram (mg) tablets, orally, on Days 1 through Day 5, for up to 8 cycles (6 months) or until progressive disease (PD), unacceptable toxicity, whichever occurs first.
Drug: Brentuximab Vedotin · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone
Brentuximab vedotin IV infusion
Cyclophosphamide IV infusion
Doxorubicin IV infusion
Prednisone tablets
Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma
ORR by IRF assessment following the completion of study treatment was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by IRF assessment using the International Working Group (IWG) Revised Response criteria following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
Time frame: Up to approximately 7 months
Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE)
An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event that occurs after administration of the first dose of study treatment and up through 30 days after the last dose of study treatment.
Time frame: Up to approximately 7 months
Number of Participants With Abnormal Changes From Baseline in Laboratory Measurements
Laboratory parameters like Potassium, Aspartate Aminotransferase (AST), Bilirubin, Serum Gamma-glutamyl Transferase (GGT), High Glucose (Hyperglycemia), Neutrophils, Leukocytes, Platelets, and Hemoglobin were assessed. Intensity of changes in laboratory parameters were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: Up to approximately 7 months
Number of Participants With Abnormal Changes From Baseline in Vital Sign Measurements (Blood Pressure)
Time frame: Up to approximately 7 months
CR Rate by IRF Assessment Per Revised Response Criteria for Malignant Lymphoma
CR rate by IRF assessment following the completion of study treatment was defined as the percentage of participants who achieved a CR by IRF assessment using the IWG Revised Response criteria following the completion of study treatment. CR was defined as disappearance of all evidence of disease.
Time frame: Up to approximately 7 months
1-Year Progression Free Survival (PFS) Rate by IRF Assessment Per Revised Response Criteria for Malignant Lymphoma
The 1-year PFS rate by IRF assessment using the IWG Revised Response criteria is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.
Time frame: Month 12
1-Year Overall Survival (OS) Rate
The 1-year OS rate is defined as the percentage of participants alive at 1 year. OS is defined as the time from the start of study treatment to the date of death due to any cause.
Time frame: Month 12
ORR by IRF Per 2014 Lugano Classification
ORR by IRF per 2014 Lugano Classification, assessed by integrated computed tomography (CT) and positron emission tomography (PET)-based responses was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
Time frame: Up to approximately 7 months
ORR by Investigator Assessment Per 2014 Lugano Classification
ORR by investigator assessment per 2014 Lugano Classification, assessed by integrated computed tomography (CT) and positron emission tomography (PET)-based responses was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by investigator assessment following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
Time frame: Up to approximately 7 months
CR Rate by IRF Per 2014 Lugano Classification
CR rate by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was defined as the percentage of participants who achieved a CR by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease.
Time frame: Up to approximately 7 months
CR Rate by Investigator Assessment Per 2014 Lugano Classification
CR rate by investigator assessment per 2014 Lugano Classification, assessed by integrated CT and PET-based responses is defined as the percentage of participants who have achieved a CR by investigator assessment following the completion of study treatment. CR was defined as disappearance of all evidence of disease
Time frame: Up to approximately 7 months
Time to Response (TTR) by IRF Per 2014 Lugano Classification
TTR by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was the time from date of first study drug administration to date of first documented objective response (CR or PR) by IRF following the completion of study treatment for responders. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
Time frame: Up to approximately 7 months
Time to Response (TTR) by Investigator Assessment Per 2014 Lugano Classification
TTR by investigator assessment per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was the time from date of first study drug administration to date of first documented objective response (CR or PR) by investigator assessment following the completion of study treatment for responders. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
Time frame: Up to approximately 7 months
1-Year PFS Rate by IRF Per 2014 Lugano Classification
The 1-year PFS rate by IRF per 2014 Lugano Classification is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.
Time frame: Month 12
1-Year PFS Rate by Investigator Assessment Per 2014 Lugano Classification
The 1-year PFS rate by investigator assessment per 2014 Lugano Classification is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.
Time frame: Month 12
Duration of Response (DOR) by Investigator Assessment Per 2014 Lugano Classification
DOR by investigator assessment using the 2014 Lugano Classification criteria is defined as the time between the first documentation of objective tumor response (CR or PR) by investigator assessment and the first subsequent documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.
Time frame: Up to approximately 36 months
Serum Antibody-Drug Conjugate (ADC) Concentration
Antibody-Drug Conjugates (ADCs) are targeted cancer therapies that combine a monoclonal antibody with a cytotoxic drug to selectively deliver treatment to cancer cells while minimizing damage to healthy cells.
Time frame: Cycle 1:Predose on Day1 and at 30minutes (min),48and 96hours postdose;Cycle 2:Predose on Day1 and at 30min,48 and 168hours postdose;Predose on Day1 of Cycles3,5,6,7;Anytime once on Days15,21 of Cycles4,6,8;30 days post-last dose; each cycle=21days
Plasma Monomethyl Auristatin E (MMAE) Concentration
The plasma concentration of MMAE is a critical factor in determining the efficacy and safety of ADCs.
Time frame: Cycle 1:Predose on Day1 and at 30minutes (min),48and 96hours postdose;Cycle 2:Predose on Day1 and at 30min,48 and 168hours postdose;Predose on Day1 of Cycles3,5,6,7;Anytime once on Days15,21 of Cycles4,6,8;30 days post-last dose; each cycle=21days
Number of Participants Who Are Antidrug Antibodies (ADA) Negative, ADA Transiently and Persistently Positive
Time frame: Pre-infusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days.
ADA Titer in Participants Positive for ADA Post Baseline
Time frame: Pre-infusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days.
Number of Participants With Negative and Positive Neutralizing Antibody Status (NAb)
Time frame: Preinfusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days
Participants took part in the study at 14 investigative sites in China from 10 February 2023 to 27 April 2025. The study is ongoing.
| Milestone | Brentuximab Vedotin + CHP |
|---|---|
| Started | 52 |
| Completed | 0 |
| Not completed | 52 |
| Withdrew: Death | 3 |
| Withdrew: Lost to follow up | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Ongoing | 46 |
ORR by IRF assessment following the completion of study treatment was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by IRF assessment using the International Working Group (IWG) Revised Response criteria following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
| percentage of participants | Brentuximab Vedotin + CHP |
|---|---|
| Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma | 96.2 (86.8 to 99.5) |
An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event that occurs after administration of the first dose of study treatment and up through 30 days after the last dose of study treatment.
| percentage of participants | Brentuximab Vedotin + CHP |
|---|---|
| Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) | 100 |
Laboratory parameters like Potassium, Aspartate Aminotransferase (AST), Bilirubin, Serum Gamma-glutamyl Transferase (GGT), High Glucose (Hyperglycemia), Neutrophils, Leukocytes, Platelets, and Hemoglobin were assessed. Intensity of changes in laboratory parameters were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
| Participants | Brentuximab Vedotin + CHP |
|---|---|
| Postbaseline Shift From Grade 0 to Grade 4 Low Potassium | 1 |
| Postbaseline Shift From Grade 0 to Grade 3 AST | 1 |
| Postbaseline Shift From Grade 0 to Grade 3 Bilirubin | 1 |
| Postbaseline Shift From Grade 0 to Grade 3 Serum GGT | 2 |
| Postbaseline Shift From Grade 0 to Grade 3 High Glucose (Hyperglycemia), | 2 |
| Postbaseline Shift From Grade 0 to Grade 3 Low Potassuium | 2 |
| Postbaseline Serum Total Bilirubin >=2 ULN | 0 |
| Postbaseline Shift From CTCAE Grade 0 to Grade 4 Low Neutrophil Count | 8 |
| Postbaseline Shift From CTCAE Grade 0 to Grade 4 Low Leukocyte Count | 6 |
| Postbaseline Shift From CTCAE Grade 0 to Grade 4 Low Platelet Count | 1 |
| Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Leukocyte Count | 6 |
| Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Neutrophil Count | 3 |
| Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Platelet Count | 2 |
| Postbaseline Shift From CTCAE Grade 0 to Grade 3 Low Hemoglobin | 1 |
| Postbaseline Shift From CTCAE Grade 1 to Grade 3 Low Hemoglobin | 3 |
| Postbaseline Shift From CTCAE Grade 1 to Grade 3 Low Leucocyte Count | 1 |
| Participants | Brentuximab Vedotin + CHP |
|---|---|
| Number of Participants With Abnormal Changes From Baseline in Vital Sign Measurements (Blood Pressure) | 1 |
CR rate by IRF assessment following the completion of study treatment was defined as the percentage of participants who achieved a CR by IRF assessment using the IWG Revised Response criteria following the completion of study treatment. CR was defined as disappearance of all evidence of disease.
| percentage of participants | Brentuximab Vedotin + CHP |
|---|---|
| CR Rate by IRF Assessment Per Revised Response Criteria for Malignant Lymphoma | 75.0 (61.1 to 86.0) |
The 1-year PFS rate by IRF assessment using the IWG Revised Response criteria is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.
Results for this outcome have not been posted.
The 1-year OS rate is defined as the percentage of participants alive at 1 year. OS is defined as the time from the start of study treatment to the date of death due to any cause.
Results for this outcome have not been posted.
ORR by IRF per 2014 Lugano Classification, assessed by integrated computed tomography (CT) and positron emission tomography (PET)-based responses was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
| percentage of participants | Brentuximab Vedotin + CHP |
|---|---|
| ORR by IRF Per 2014 Lugano Classification | 92.3 (81.5 to 97.9) |
ORR by investigator assessment per 2014 Lugano Classification, assessed by integrated computed tomography (CT) and positron emission tomography (PET)-based responses was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by investigator assessment following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
| percentage of participants | Brentuximab Vedotin + CHP |
|---|---|
| ORR by Investigator Assessment Per 2014 Lugano Classification | 94.2 (84.1 to 98.8) |
CR rate by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was defined as the percentage of participants who achieved a CR by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease.
| percentage of participants | Brentuximab Vedotin + CHP |
|---|---|
| CR Rate by IRF Per 2014 Lugano Classification | 76.9 (63.2 to 87.5) |
CR rate by investigator assessment per 2014 Lugano Classification, assessed by integrated CT and PET-based responses is defined as the percentage of participants who have achieved a CR by investigator assessment following the completion of study treatment. CR was defined as disappearance of all evidence of disease
| percentage of participants | Brentuximab Vedotin + CHP |
|---|---|
| CR Rate by Investigator Assessment Per 2014 Lugano Classification | 76.9 (63.2 to 87.5) |
TTR by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was the time from date of first study drug administration to date of first documented objective response (CR or PR) by IRF following the completion of study treatment for responders. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
| months | Brentuximab Vedotin + CHP |
|---|---|
| Time to Response (TTR) by IRF Per 2014 Lugano Classification | 2.727 (2.694 to 2.760) |
TTR by investigator assessment per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was the time from date of first study drug administration to date of first documented objective response (CR or PR) by investigator assessment following the completion of study treatment for responders. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.
| months | Brentuximab Vedotin + CHP |
|---|---|
| Time to Response (TTR) by Investigator Assessment Per 2014 Lugano Classification | 2.727 (2.694 to 2.760) |
The 1-year PFS rate by IRF per 2014 Lugano Classification is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.
Results for this outcome have not been posted.
The 1-year PFS rate by investigator assessment per 2014 Lugano Classification is defined as the percentage of participants alive and progression free at 1 year. PFS is defined as the time from the start of study treatment to the date of first documentation of PD, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.
Results for this outcome have not been posted.
DOR by investigator assessment using the 2014 Lugano Classification criteria is defined as the time between the first documentation of objective tumor response (CR or PR) by investigator assessment and the first subsequent documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or PD, whichever occurs first.
Results for this outcome have not been posted.
Antibody-Drug Conjugates (ADCs) are targeted cancer therapies that combine a monoclonal antibody with a cytotoxic drug to selectively deliver treatment to cancer cells while minimizing damage to healthy cells.
| nanograms per milliliter (ng/mL) | Brentuximab Vedotin + CHP |
|---|---|
| Cycle 1 - Predose | NA ± NA |
| Cycle 1 - End of infusion (30 min) | 32278.6310 ± 6782.22537 |
| Cycle 1 - Day 3 (48 hr) | 8017.2624 ± 3262.42585 |
| Cycle 1 - Day 5 (96 hr) | 4703.5579 ± 1795.74382 |
| Cycle 2 - Predose | 364.0768 ± 151.95902 |
| Cycle 2 - End of infusion (30 min) | 31953.2729 ± 8062.68391 |
| Cycle 2 - Day 3 (48 hr) | 8944.7727 ± 3432.10921 |
| Cycle 2 - Day 8 (168 hr) | 2674.7550 ± 626.08923 |
| Cycle 3 - Predose | 558.8526 ± 181.81833 |
| Cycle 4 - 15 to 21 Days Postdose | 1044.3557 ± 361.75958 |
| Cycle 5 - Predose | 617.9578 ± 247.80106 |
| Cycle 6 - Predose | 623.6881 ± 178.29961 |
| Cycle 6 - 15 to 21 Days Postdose | 1052.5095 ± 412.67066 |
| Cycle 7 - Predose | 660.0101 ± 198.78143 |
| Cycle 8 - 15 to 21 Days Postdose | 1091.6060 ± 364.72862 |
| Last - 15 to 21 Days Postdose | 1071.2758 ± 386.93255 |
The plasma concentration of MMAE is a critical factor in determining the efficacy and safety of ADCs.
| picogram per milliliter (pg/mL) | Brentuximab Vedotin + CHP |
|---|---|
| Cycle 1 - Predose | 1070.00 ± NA |
| Cycle 1 - End of infusion (30 min) | 342.80 ± 430.172 |
| Cycle 1 - Day 3 (48 hr) | 4038.50 ± 2251.734 |
| Cycle 1 - Day 5 (96 hr) | 3664.39 ± 2682.503 |
| Cycle 2 - Predose | 94.35 ± 83.847 |
| Cycle 2 - End of infusion (30 min) | 211.03 ± 142.401 |
| Cycle 2 - Day 3 (48 hr) | 1799.23 ± 502.966 |
| Cycle 2 - Day 8 (168 hr) | 1481.65 ± 661.914 |
| Cycle 3 - Predose | 91.21 ± 52.715 |
| Cycle 4 - 15 to 21 Days Postdose | 294.93 ± 251.617 |
| Cycle 5 - Predose | 107.18 ± 91.718 |
| Cycle 6 - Predose | 103.79 ± 77.201 |
| Cycle 6 - 15 to 21 Days Postdose | 329.65 ± 317.291 |
| Cycle 7 - Predose | 118.26 ± 93.931 |
| Cycle 8 - 15 to 21 Days Postdose | 241.97 ± 200.011 |
| Last - 15 to 21 Days Postdose | 286.70 ± 267.333 |
| Participants | Brentuximab Vedotin + CHP |
|---|---|
| Baseline Positive and Post-baseline Negative | 1 |
| Baseline Negative and Post-baseline Negative | 51 |
| Baseline Positive and Post-baseline Transiently Positive | 0 |
| Baseline Negative and Post-baseline Transiently Positive | 0 |
| Baseline Positive and Post-baseline Persistently Positive | 0 |
| Baseline Negative and Post-baseline Persistently Positive | 0 |
No measurements were reported for this outcome.
| Participants | Brentuximab Vedotin + CHP |
|---|---|
| NAb Positive | 0 |
| NAb Negative | 52 |
Collected over AEs including SAEs were recorded from signing the consent form up to 30 days after last dose of study treatment (approximately 7 months). Only Treatment-related SAEs were continued to be recorded during long-term follow up (up to a total of approximately 27 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brentuximab Vedotin + CHP | 3/52 (5.8%) | 18/52 (34.6%) | 52/52 (100%) |
| Event | Brentuximab Vedotin + CHP |
|---|---|
| PneumoniaInfections and infestations | 12/52 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/52 |
| Neutrophil count decreasedInvestigations | 3/52 |
| White blood cell count decreasedInvestigations | 2/52 |
| BacteraemiaInfections and infestations | 1/52 |
| Gastrointestinal infectionInfections and infestations | 1/52 |
| Haemophagocytic lymphohistiocytosisImmune system disorders | 1/52 |
| Platelet count decreasedInvestigations | 1/52 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/52 |
| Soft tissue infectionInfections and infestations | 1/52 |
| Event | Brentuximab Vedotin + CHP |
|---|---|
| White blood cell count decreasedInvestigations | 37/52 |
| AnaemiaBlood and lymphatic system disorders | 35/52 |
| Neutrophil count decreasedInvestigations | 35/52 |
| Lymphocyte count decreasedInvestigations | 27/52 |
| Alanine aminotransferase increasedInvestigations | 26/52 |
| Aspartate aminotransferase increasedInvestigations | 22/52 |
| Platelet count decreasedInvestigations | 21/52 |
| NauseaGastrointestinal disorders | 18/52 |
| VomitingGastrointestinal disorders | 18/52 |
| HyperuricaemiaMetabolism and nutrition disorders | 16/52 |
The Full Analysis Set (FAS) consisted of all enrolled participants.
| Age, Continuous(years) | Brentuximab Vedotin + CHP |
|---|---|
| Mean | 48.9 ± 15.49 |
| Sex: Female, Male(Participants) | Brentuximab Vedotin + CHP |
|---|---|
| Female | 23 |
| Male | 29 |
| Ethnicity (NIH/OMB)(Participants) | Brentuximab Vedotin + CHP |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 52 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Brentuximab Vedotin + CHP |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 52 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Feb 2023 to primary completion in Apr 2025, 26 months.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Lymphoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 26 months is below that.
Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brentuximab Vedotin · Cyclophosphamide · Doxorubicin · Prednisone